Sales of Zecuity Migraine Skin Patches Halted

Share this content:
Sales of Zecuity Migraine Skin Patches Halted
Sales of Zecuity Migraine Skin Patches Halted

TUESDAY, June 14, 2016 (HealthDay News) -- Sales of the migraine treatment skin patch Zecuity (sumatriptan iontophoretic transdermal system) have been halted after patients reported suffering burns and scars where the patches were applied, Teva Pharmaceutical says.

The Israel-based company also said consumers with the disposable battery-powered patches should stop using them, the Associated Press reported.

The patch is designed to deliver a dose of medicine via a single-use, battery-powered patch that is wrapped around the upper arm or thigh. But some users have developed severe redness, skin discoloration, cracked skin, and pain where patches were applied, according to the U.S. Food and Drug Administration.

Teva said it is recalling the patches and working with the FDA to determine the cause of the skin reactions, the AP reported.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

CDC Concerned About Falling Flu Vaccination Rates

CDC Concerned About Falling Flu Vaccination Rates

Decline among vulnerable older adults is of particular concern

One in Five With Non-Valvular A-Fib Receiving Digoxin

One in Five With Non-Valvular A-Fib Receiving Digoxin

Indication for digoxin use was considered inappropriate in 59.8 percent in Turkish cohort

Rapid, Successful Response to ART for Many Patients With HIV

Rapid, Successful Response to ART for Many Patients ...

Factors associated with virological success include having undetectable viral load, use of three drugs

is free, fast, and customized just for you!

Already a member?

Sign In Now »